ALT Stock Analysis: Buy, Sell, or Hold?
ALT - Altimmune, Inc. Common Stock
$2.85
-0.07 (-2.40%)
▼
5d:
-7.77%
30d:
-18.8%
90d:
-37.09%
HOLD
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 19, 2026
TODAY
Smart Money Accumulation
ALT is down 7.8% this week, but smart money is accumulating calls. Top strike: $4 2026-06-18 with 4,590 OI. Call ratio: 81% View Scanner →
Strength: 6.9/10
Get Alerted When ALT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
30 traders called ALT this week
96% bullish • 2 bearish
96% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ALT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ALT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ALT is currently trading at $2.85, which is considered oversold relative to its 30-day fair value range of $2.86 to $3.40.
Technical Outlook: Technically, ALT is in a strong downtrend. The price is currently testing key support at $2.81. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $18.38 (+544.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ALT is in a strong downtrend. The price is currently testing key support at $2.81. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $18.38 (+544.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.86 -
$3.40
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 544.7% below Wall St target ($18.38)
- CAUTION: Recommendation downgraded due to -7.8% 5-day decline
Trading Range Analysis
30-Day Trading Range
$2.86 -
$3.40
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.81
Resistance Level
$3.26
Current Trend
Strong Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.09
Wall Street Target
$18.38
(+544.7%)
Revenue Growth (YoY)
420.0%
Share & Embed Analysis
Last updated: May 18, 2026 8:26 AM ET
Data refreshes hourly during market hours. Next update: 9:26 AM
Data refreshes hourly during market hours. Next update: 9:26 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALT showing a specific setup today?
Insider Activity (6 Months)
6
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Gregory L Weaver
BUY
5000 shares
2026-03-06
Jerome Benedict Durso
BUY
20000 shares
2026-03-06
Wayne Pisano
BUY
5000 shares
2026-01-08
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$55 | 57 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 55 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$242 | 64 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 61 BUY |
